Skip to main content

Ibrutinib Dosage

Medically reviewed by Drugs.com. Last updated on Sep 5, 2023.

Applies to the following strengths: 70 mg/mL; 140 mg; 70 mg; 280 mg; 420 mg; 560 mg

Usual Adult Dose for Chronic Lymphocytic Leukemia

420 mg orally once a day
Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Uses:

Usual Adult Dose for Waldenstrom's Macroglobulinemia

420 mg orally once a day
Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: For the treatment of patients with Waldenstrom's macroglobulinemia (WM)

Usual Adult Dose for Graft Versus Host Disease

420 mg orally once a day
Duration of therapy: Until progression of chronic graft-versus-host disease (cGVHD), recurrence of an underlying malignancy, or unacceptable toxicity

Comments:


Use: For the treatment of patients with cGVHD after failure of 1 or more lines of systemic therapy

Usual Pediatric Dose for Graft Versus Host Disease

1 to less than 12 years: 240 mg/m2 orally once a day


Oral Suspension:
Dosage based on BSA (to achieve 240 mg/m2):

Capsules/Tablets:
Dosage based on BSA (to achieve 240 mg/m2):

12 years and older: 420 mg orally once a day

Duration of Therapy: Until progression of cGVHD, recurrence of an underlying malignancy, or unacceptable toxicity

Comments:

Use: For the treatment of patients with cGVHD after failure of 1 or more lines of systemic therapy

Renal Dose Adjustments

Mild and moderate renal dysfunction (CrCl greater than 25 mL/min): No adjustment recommended
Severe renal dysfunction (CrCl less than 25 mL/min): Data not available

Comments:

Liver Dose Adjustments

Adult patients with B-cell malignancies:


Patients with cGVHD:

Comments:

Dose Adjustments

DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS:
This drug should be interrupted for the adverse reactions listed below. Once the adverse reaction has improved to grade 1 or baseline (recovery), the recommended dosage modifications should be followed.

Dose Modification for CLL/SLL, WM, and Patients 12 Years and Older with cGVHD After Recovery (Starting Dose = 420 mg):
Cardiac arrhythmias:


Cardiac failure:

Hematological toxicities:

Neutropenia with infection or fever:

Other nonhematological toxicities:

Dose Modification for Patients 1 to Less Than 12 Years with cGVHD After Recovery (Starting Dose = 240 mg/m2):
Cardiac arrhythmias:

Cardiac failure:

Hematological toxicities:

Neutropenia with infection or fever:

Other nonhematological toxicities:

Oral Suspension:
Dosage based on BSA (to achieve 160 mg/m2):

Capsules/Tablets:
Dosage based on BSA (to achieve 160 mg/m2):

Oral Suspension:
Dosage based on BSA (to achieve 80 mg/m2):

Capsules/Tablets:
Dosage based on BSA (to achieve 80 mg/m2):

DOSAGE MODIFICATIONS FOR USE WITH CYP450 3A INHIBITORS:
Patients with B-cell malignancies:

Patients 12 years and older with cGVHD:

Patients 1 to less than 12 years with cGVHD:

After discontinuation of a CYP450 3A inhibitor, the previous dose of this drug should be resumed.

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established for cGVHD in patients younger than 1 year. Safety and efficacy have not been established in patients younger than 18 years with CLL/SLL, CLL/SLL with 17p deletion, or WM.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.